CompletedPhase 2

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis

United States59 participantsStarted 2019-05-20

Plain-language summary

A study to evaluate the efficacy and safety, and pharmacokinetic (PK) profile of multiple doses of imsidolimab (ANB019) in adults with palmoplantar pustulosis (PPP)

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Clinically confirmed diagnosis of PPP * Disease duration of at least 6 months prior to screening * Present with active pustules on palms or/and soles at screening Exclusion Criteria: * Any other ongoing inflammatory disease that interfere with the investigator's ability to evaluate the subject's response to therapy * History of recurrent or active/serious infection * Ongoing use of psoriasis prohibited medication Other protocol-defined inclusion/exclusion criteria may apply

What they're measuring

Change From Baseline in Palmoplantar Pustulosis Psoriasis Area Severity Index (PPPASI)

Timeframe: Baseline to Week 16

Number of Participants With Treatment-emergent Adverse Events (TEAEs)

Timeframe: From first dose of any study drug to Week 24

Trial details

NCT IDNCT03633396

SponsorVanda Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2021-04-23

Results submitted2022-05-05

View on ClinicalTrials.gov More Palmoplantar Pustulosis trials